60 Degrees Pharma Files Proxy Statement for July Meeting

Ticker: SXTPW · Form: DEF 14A · Filed: May 30, 2024 · CIK: 1946563

60 Degrees Pharmaceuticals, Inc. DEF 14A Filing Summary
FieldDetail
Company60 Degrees Pharmaceuticals, Inc. (SXTPW)
Form TypeDEF 14A
Filed DateMay 30, 2024
Risk Levellow
Pages16
Reading Time19 min
Sentimentneutral

Sentiment: neutral

Topics: proxy-statement, governance, annual-meeting

TL;DR

60 Degrees Pharma proxy filed for July 16th meeting - vote on directors & pay.

AI Summary

60 Degrees Pharmaceuticals, Inc. filed a Definitive Proxy Statement (DEF 14A) on May 30, 2024, for its annual meeting scheduled for July 16, 2024. The filing outlines the company's governance and proposals to be voted on by shareholders, including the election of directors and executive compensation.

Why It Matters

This filing provides shareholders with crucial information regarding the company's leadership, executive pay, and key decisions to be made at the upcoming annual meeting, impacting their investment.

Risk Assessment

Risk Level: low — This is a routine proxy filing providing information to shareholders and does not inherently indicate new risks.

Key Players & Entities

  • 60 DEGREES PHARMACEUTICALS, INC. (company) — Registrant
  • 20240530 (date) — Filing Date
  • 20240716 (date) — Meeting Date
  • 202-327-5422 (phone_number) — Business Phone

FAQ

What is the purpose of this DEF 14A filing?

The purpose of this DEF 14A filing is to provide shareholders with information regarding the company's annual meeting, including proposals to be voted on, such as the election of directors and executive compensation.

When is the annual meeting of 60 Degrees Pharmaceuticals, Inc. scheduled?

The annual meeting of 60 Degrees Pharmaceuticals, Inc. is scheduled for July 16, 2024.

Who is the filer of this proxy statement?

The filer of this proxy statement is 60 Degrees Pharmaceuticals, Inc.

What is the company's fiscal year end?

The company's fiscal year end is December 31.

What is the business address of 60 Degrees Pharmaceuticals, Inc.?

The business address of 60 Degrees Pharmaceuticals, Inc. is 1025 Connecticut Avenue NW, Suite 1000, Washington, DC 20036.

Filing Stats: 4,765 words · 19 min read · ~16 pages · Grade level 13.7 · Accepted 2024-05-30 14:15:42

Filing Documents

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 17 DELINQUENT SECTION 16(A) REPORTS 20

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS 20 CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS 21 PROPOSAL 2: APPROVAL OF AMENDMENT TO THE 2022 EQUITY INCENTIVE PLAN TO INCREASE TOTAL NUMBER OF AUTHORIZED SHARES BY 5,000,000 SHARES 22 PROPOSAL 3: APPROVAL OF AMENDMENT OF CERTIFICATE OF INCORPORATION TO EFFECT A REVERSE STOCK SPLIT AT A SPLIT RATIO OF 1:5 TO 1:12, INCLUSIVE, AS DETERMINED BY THE BOARD OF DIRECTORS IN ITS SOLE DISCRETION 28 PROPOSAL 4: APPROVAL OF A MODIFICATION TO THE STRIKE PRICE OF THE OPTIONS TO COMPLY WITH NASDAQ LISTING RULE 5635(C) 33 PROPOSAL 5: APPROVAL OF THE ISSUANCE OF OPTIONS GRANTED TO A CONSULTANT TO COMPLY WITH NASDAQ LISTING RULE 5635(C) 34 PROPOSAL 6: RATIFICATION OF APPOINTMENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM 34 PROPOSAL 7: APPROVAL OF THE ADJOURNMENT OF THE ANNUAL MEETING, IF NECESSARY, TO SOLICIT ADDITIONAL PROXIES IN THE EVENT THERE ARE NOT SUFFICIENT VOTES IN FAVOR OF THE 2022 PLAN AMENDMENT PROPOSAL, THE CERTIFICATE OF INCORPORATION AMENDMENT PROPOSAL, THE STRIKE PRICE MODIFICATION AMENDMENT PROPOSAL AND THE OPTION ISSUANCE PROPOSAL AT THE TIME OF THE ANNUAL MEEETING 35 ADDITIONAL INFORMATION 36 i 60 DEGREES PHARMACEUTICALS, INC. 1025 Connecticut Avenue NW Suite 1000 Washington, D.C. 20036 PROXY STATEMENT For Annual Meeting of Stockholders to Be Held on July 16, 2024 The Board of Directors (the “Board”) of 60 Degrees Pharmaceuticals, Inc., a Delaware corporation (“60 Degrees Pharmaceuticals,” “60P,” “Company,” “we,” “us” or “our”), solicits the enclosed proxy for use at the 2024 Annual Meeting of Stockholders of the Company (“Annual Meeting”) to be held on July 16, 2024, only via live audio webcast over the telephone by following the instructions set forth here at “ Questions and Answers About the Meeting And Voting —

View Full Filing

View this DEF 14A filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.